1. Home
  2. SPRO

SPRO

Spero Therapeutics Inc.

Logo Spero Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Founded: 2013 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 91.0M IPO Year: 2017
Target Price: $7.00 AVG Volume (30 days): 317.0K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.43 EPS Growth: N/A
52 Week Low/High: $0.99 - $2.00 Next Earning Date: 05-09-2024
Revenue: $103,781,000 Revenue Growth: 93.95%
Revenue Growth (this year): -52.59% Revenue Growth (next year): -0.83%

Share on Social Networks: